从1994年 FGFR3靶点被证实与ACH相关，到2021年Vosoritide获批上市，ACH患者等待了近30年，才迎来首款针对性治疗药物。而随着Infigratinib叩响上市的大门，以及身后一众迭代疗法的逼近，ACH精准治疗的新大门正加速开启。这也是罕见病从被行业忽略到逐渐被重视的真实缩影。
A new daily pill could be a more effective GLP-1 tablet for weight loss, according to a clinical trial that may pave the way for an improved non-injection alternative to Wegovy and Mounjaro.
。同城约会是该领域的重要参考
The announcement came two days after release of a sharply-worded report from NASA's independent Aerospace Safety Advisory Panel that deemed the existing plans too risky.
check processing system. Use of checks was rapidly increasing, as were total